Robert Wechsler-Reya

Professor

Columbia University Irving Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Deregulation of neuroblastoma-derived myc (N-myc) is a leading cause of malignant brain tumors in children. To target N-myc-driven medulloblastoma, most research has focused on identifying genomic alterations or on the analysis of the medulloblastoma transcriptome. Here, we have broadly characterized the translatome of medulloblastoma and shown that N-myc unexpectedly drives selective translation of transcripts that promote protein homeostasis. Cancer cells are constantly exposed to proteotoxic stress associated with alterations in protein production or folding. It remains poorly understood how cancers cope with proteotoxic stress to promote their growth. Here, our data revealed that N-myc regulates the expression of specific components (∼5%) of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E. Reducing eIF4E levels in mouse models of medulloblastoma blocked tumorigenesis. Importantly, targeting Hsp70, a protein folding chaperone translationally regulated by N-myc, suppressed tumor growth in mouse and human medulloblastoma xenograft models. These findings reveal a previously hidden molecular program that promotes medulloblastoma formation and identify new therapies that may have impact in the clinic. Significance: Translatome analysis in medulloblastoma shows that N-myc drives selective translation of transcripts that promote protein homeostasis and that represent new therapeutic vulnerabilities.

Year:

2025

Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation therapy. A major challenge is the coexistence of molecularly distinct malignant cell states with potentially orthogonal drug sensitivities. To address this challenge, we leveraged established network-based methodologies to elucidate Master Regulator (MR) proteins representing mechanistic, non-oncogene dependencies of seven coexisting subpopulations identified by single-cell analysis—whose enrichment in essential genes was validated by pooled CRISPR/Cas9 screens. Perturbational profiles of 372 clinically relevant drugs helped identify those able to invert the activity of subpopulation-specific MRs for follow-up in vivo validation. While individual drugs predicted to target individual subpopulations—including avapritinib, larotrectinib, and ruxolitinib—produced only modest tumor growth reduction in orthotopic models, systemic co-administration induced significant survival extension, making this approach a valuable contribution to the rational design of combination therapy.

Year:

2024

Collaborators (10)

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Robyn Gartrell

Assistant Professor of Pediatrics in Division of Pediatric Hematology/Oncology/SCT

Johns Hopkins University School of Medicine

UNITED STATES
View details

Duygu Kuzuoglu Ozturk

Assistant Prof

Sabancı University

TURKEY
View details

Hong-Jian Wei

Research Assistant Professor

Virginia Tech

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Jason E. Gestwicki

Professor

University of California, San Francisco

UNITED STATES
View details

Miller Huang

Assistant Professor

University of Southern California

UNITED STATES
View details

Joanna J. Phillips

Profesor

University of California, San Francisco

UNITED STATES
View details

Theophilos Tzaridis

Sanford Burnham Prebys Medical Discovery Institute

UNITED STATES
View details

William A. Weiss

Director of outpatient child neurology

University of California

UNITED STATES
View details